, the rate of side effects (aRR 1.18, 95%CI 1.09-1.27) , and absence of culture conversion during the intensive phase (aRR 0.47, 95%CI 0.31-0.71) were independently associated with default from treatment. In the qualitative study, poor treatment tolerance, a perception that treatment was inefficient, lack of information, incorrect perception of being cured, working factors and behavioural problems were factors related to treatment default.
1.27), the rate of treatment interruption based on patient's decision (aRR 1.03, 95%CI 1.02-1.05), the rate of side effects (aRR 1.18, 95%CI 1.09-1.27), and absence of culture conversion during the intensive phase (aRR 0.47, 95%CI 0.31-0.71) were independently associated with default from treatment. In the qualitative study, poor treatment tolerance, a perception that treatment was inefficient, lack of information, incorrect perception of being cured, working factors and behavioural problems were factors related to treatment default.
C O N C L U S I O N :
In addition to economic reasons, poor tolerance of and poor response to treatment were the main factors associated with treatment default. K E Y W O R D S : tuberculosis; default; resistance THE BURDEN OF TUBERCULOSIS (TB) is high in the former Soviet Union countries, which also face high levels of drug-resistant tuberculosis (DR-TB). 1, 2 Armenia belongs to the 27 countries with a high burden of multidrug-resistant tuberculosis (MDR-TB, defi ned as Mycobacterium tuberculosis resistant to both isoniazid [H, INH] and rifampicin [R, RMP]). 1 The incidence of new TB cases in Armenia is estimated at 73 per 100 000 population (95% confi dence interval [CI] 59-88). MDR-TB accounted for 14.5% (95%CI 1.6-18.0) of all TB cases in 2007. 2, 3 Since 2005, Médecins Sans Frontières (MSF) has provided support to the Armenian National Tuberculosis Programme (NTP) in the treatment of DR-TB.
DR-TB is of special concern, as it can undermine efforts to control the TB epidemic. 4, 5 Monitoring outcomes of DR-TB treatment is an important aspect of the surveillance activities adopted to control the spread of M. tuberculosis-resistant strains and identify weak areas in treatment management. 6 Default, death and treatment failure are usually used as a measure of poor treatment outcome, whereas the number of patients who achieve cure or who complete treatment is used as an indicator of success. 7 Studies on MDR-TB have reported that a large proportion of unsuccessful outcomes are attributable to default and death. [8] [9] [10] This is a major problem in the programme in Yerevan, the capital of Armenia, where despite efforts made to ensure adherence to treatment, 24.7% of patients default from treatment and 7.6% die (source: NTP data 2005-2011). Reasons for treatment default among patients with DR-TB should be further considered to enhance adherence to treatment in settings where DR-TB is a public health priority. In the present study, we assessed factors related to treatment default among DR-TB patients receiving care in Yerevan using retrospective analysis of programme data. To strengthen our fi ndings, we also performed a qualitative study to identify patient and health provider beliefs concerning default from DR-TB treatment.
METHODS

Setting
The NTP/MSF DR-TB programme covers the entire city of Yerevan. Treatment regimens are individualised
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based on results of drug susceptibility testing; at least four effective drugs are given for 15-24 months according to World Health Organization (WHO) guidelines. 6 Injectable second-line drugs (kanamycin, capreomycin) are given until 4 months after culture conversion to negative, and for a minimum of 6 months (intensive phase). Patients are hospitalised until they have two sputum-negative culture or smear results (not necessarily throughout the intensive phase). Treatment administration is under direct observation (DOT) throughout the full course of treatment. Patients undergo medical assessments daily during the fi rst month of treatment, weekly until the end of the intensive phase and monthly during the continuation phase, with careful management of adverse events. Psychological and socio-economic support (fi nancial and nutrition support, transport reimbursement) are provided. The programme was approved by the WHO Green Light Committee in 2006.
Quantitative study
Study population
The study included all patients with laboratoryc onfi rmed DR-TB, either MDR-TB or polydrugr esistant TB (PDR-TB, i.e., resistant to more than one fi rst-line drug other than MDR-TB), who initiated treatment from 2005 to 2011.
Defi nition of exposure
Data were collected in Koch'6, a software programme developed by MSF for the clinical management of patients with DR-TB that is completed routinely for all patients by two trained data clerks. The database did not include any personal information. Variables abstracted included socio-demographic characteristics, history of substance abuse, TB treatment history, clinical and radiographic fi ndings at baseline, bacteriological baseline status and resistance pattern. Treatment information included emergence of co-morbidities and drug side effects, treatment changes and interruptions and adherence to treatment. Treatment adherence was assessed monthly by the ratio of treatment doses received under DOT divided by the number of doses prescribed. Treatment interruptions were defi ned as interruption of full treatment for at least one day, and were separated by the clinician into interruptions due to side effects or another medical reason and interruptions due to patient's decision (social reasons, refusal, etc.). Treatment changes corresponded to any change in treatment (either dose or full drug) without treatment interruption.
Outcome defi nitions
Treatment outcomes were assessed based on WHO recommended defi nitions. 6 A defaulter was defi ned as a patient who interrupted the full course of treatment for at least 2 consecutive months. The default rate was calculated as the total number of patients who defaulted by year of admission divided by the total number of patients initiated on treatment in that year; the most recent cohorts were excluded, as a significant proportion of patients were still on treatment.
Statistical analysis
We compared patients who had defaulted from treatment with those who were cured, completed or had failed treatment. Patients still on treatment, transferred out or who died during treatment were excluded. Characteristics associated with treatment default were assessed using generalised linear models for the binomial family. All variables with P ⩽ 0.20 in univariate analysis were included in a multivariable analysis. Data were analysed using Stata v10.1 for Windows (Stata Corp, College Station, TX, USA). Correlation between variables was checked prior to their inclusion in the multivariate analysis. Missing data were not replaced or imputed. The main interactions were assessed using a level of signifi cance of P ⩽ 0.05.
Qualitative study
The qualitative survey included semi-structured interviews of adult patients who had defaulted from DR-TB treatment and focus group discussions with health care workers and pychosocial support teams. We also recorded reasons for stopping treatment, which are routinely collected by the adherence team. All defaulters were traced and invited by telephone to participate in a face-to-face interview outside the DR-TB programme facility with a trained Armenian psychology student who was not involved in the DR-TB programme. Signed informed consent was provided by the patients. Focus group discussions were conducted by an experienced psychologist. The recordings were transcribed in Armenian and translated verbatim into English. To reduce bias during the interview, interviewers were not informed about the study objectives and were trained on how to obtain information without infl uencing the subject response. Data analyses were performed using an interim analysis process. The major themes were listed according to the objectives of the study before starting the analyses (a priori codes), and were enriched if other themes were found to be relevant to the study objectives (inductive codes). The selected themes were identifi ed in the transcribed text (coding) by a qualitative researcher. The study was conducted in November 2011.
Ethical approval was obtained from the ethics committee of the University of Psychology of Yerevan and the Comité Consultatif de Protection des Personnes, Saint Germain en Laye, France.
RESULTS
Quantitative study
During the study period, 486 patients initiated DR-TB treatment in Yerevan. Of these, 100 were still on treatment at the time of the study, 193 had achieved treatment success (134 cured, 59 completed), 24 had died, 18 were transferred out, 51 had failed treatment and 97 had defaulted. From 2006 to 2009 the default rate ranged between 22% and 27%. The median duration of treatment for defaulting patients was 6.5 months (interquartile range [IQR] 4.3-12.0). Of the 97 defaulter patients, 69 (71.1%) had defaulted during the intensive phase and 86 (88.7%) while on ambulatory treatment.
Among the socio-demographic factors analysed, being male, having been in prison and alcohol intake were statistically associated with defaulting from treatment. Although previous TB treatment history and outcomes of previous treatment were not associated with default, the number of past courses of antituberculosis treatment was signifi cantly associated with default (Table 1) . We found no association with clinical condition at admission; however, smear status, resistance pattern (PDR-TB vs. MDR-TB) and the number of drugs to which the patient was resistant were signifi cantly associated with default ( Table 2 ). The number of treatment changes and treatment interruptions (due to patient decision and side effects) per year of treatment, the monthly treatment adherence rate and the annual rate of side effects were signifi cantly associated with treatment default. Patients who culture-converted during the intensive phase were less likely to default (Table 3) .
In the multivariate analysis, the number of drugs to which the patient was resistant at admission, the rate of treatment interruption based on the patient's decision and on side effects and the absence of culture conversion during the intensive phase of the treatment were independently associated with defaulting from treatment ( Table 4 ). An analysis including only MDR-TB patients showed similar results (data not shown).
Findings of the qualitative study
Of 97 defaulters reported in the programme records, four were registered twice as having defaulted. Of the 93 patients, only 12 could be interviewed (Figure) . All patients interviewed mentioned diffi culties in dealing with side effects, and 11 reported side effects as one of the main reasons for defaulting. The second factor most frequently mentioned was fear that the treatment was not effective or even harmful (n = 9). Six patients said that they did not think they needed the treatment any longer (they felt better or cured after a few months of treatment or several negative culture results). Four patients mentioned that the information received on the disease and its treatment was not suffi cient or did not target their specifi c needs (mainly regarding side effects). Five patients reported having more diffi culty in adhering to treatment during the ambulatory phase (Table 5) . From the perspective of programme staff, side effects and the lack of information on DR-TB disease and treatment were identifi ed as the main factors associated with defaulting. Some personnel did not feel trained enough to deliver proper messages on DR-TB. They agreed that education should be adapted to the patients' needs and should continue throughout treatment. Most of the personnel agreed that patients complied better during hospitalisation and that discharge to home-based care was a critical period due to social issues or due to DOT during ambulatory treatment. Consumption of alcohol or illicit drugs to which the patient was resistant at baseline was an independent predictor of defaulting from treatment, there was no association with the extent and severity of the disease or sputum smear microscopy results at treatment initiation. That's why we have escaped from there I have been taking so many drugs, so many X-rays were done, they did much and we had no results. I don't know how much influenced those drugs on the lungs. They said that I had to continue the treatment up to 24 months. They said that nobody can guarantee that it will not be repeated.
Feeling better or cured I was feeling better so I stopped. I didn't want to continue, I was cured. When I interrupted my treatment, I was thinking I was cured.
Lack of specific information
Since I restarted my treatment, nobody provided information about the treatment; they thought I knew everything already.
Difficulties during the out-patient phase of the treatment
It's a difficult moment while passing from one to the other [hospital to ambulatory care]. In the hospital you were not getting crazy and you could eat after the drugs. When I was going to take my drugs (in the polyclinic) I was feeling bad. I took my drugs for about 1 month and I didn't go any more to the polyclinic, since the side effects were too strong and I was getting worse.
Defaulting due to other factors: social issues, duration of treatment, etc.
I tolerated badly the treatment but that was not the reason for defaulting, I had to take care of one of my relatives who was sick. It is an unbearable treatment. How you can take drugs for 3 years?
and the long duration of treatment were also cited as factors related with defaulting (Table 6 ). Finally, the defi nition of treatment failure was debated: there was a perception that some patients were failing treatment but defaulted before being classifi ed as failures.
The following reasons for not returning for treatment were recorded by the adherence team: 21 (24.4%) return to work (10 of whom left the country), 20 (23.3%) behavioural problems (mainly substance abuse), 15 (17.4%) lack of belief in treatment benefi ts, 10 (11.6%) side effects, 8 (9.3%) comorbidities, 7 (8.1%) feeling healthy, and 3 (3.5%) complex social situation. For 11 patients, the reason was not noted.
DISCUSSION
Our study showed that patients with poor treatment tolerance, based on the number of side effects, and patients with poor treatment response, based on the absence of culture conversion during intensive phase, were at higher risk of defaulting from treatment. This was consistent in both the quantitative and qualitative analyses in the study. Whereas the number of drugs To our knowledge, only three studies have looked at factors related to default from DR-TB treatment. Holtz et al. found that treatment default was mostly associated with substance use, dissatisfaction with health care worker attitudes and low socio-economic status. 11 Gler et al. reported that patients receiving a greater number of drugs during treatment were at higher risk of defaulting, while treatment decentralisation after culture conversion had a protective role. 12 In the same study, patient mobility and migration were associated with treatment default. Franke et al. found that treatment default was predicted by substance use and substandard housing conditions. 13 In the latter two studies, the role of side effects was not included in the statistical model. These studies were performed in a context very different to Armenia, i.e., South Africa, 11 Philippines 12 and Peru. 13 The role of side effects on treatment adherence has been discussed previously for drug-susceptible TB and other diseases that require long-term treatment, such as human immunodefi ciency virus/acquired immunedefi ciency syndrome. [14] [15] [16] [17] [18] [19] [20] The treatment of DR-TB is known to cause frequent severe side effects. [21] [22] [23] In the project in Yerevan, free, good quality monitoring and management of side effects was provided thanks to MSF support. Nonetheless, patients and staff agreed that better information about side effects could help patients to tolerate treatment. This is consistent with the fi nding of a recent meta-analysis that showed that patient education was one of the most effective interventions for reducing default in DR-TB. 24 Engaging community health workers as DOT providers in ambulatory treatment was also highlighted as an important intervention. 24 Education could be particularly benefi cial during the out-patient phase of treatment. The fi rst months of the out-patient phase were identifi ed as a sensitive period for treatment adherence. Potential explanations were the loss of trust in the need for treatment during the ambulatory phase, the incorrect belief of being cured once discharged from the hospital, the perception of obtaining less support for the management of side effects and the lack of health education. On the other hand, patients whose clinical or bacteriological condition does not improve during hospitalisation may lose faith in treatment and decide not to continue, as supported by the fi ndings of our quantitative study.
The relationship between sex and default, shown previously for drug-susceptible TB, 15, [25] [26] [27] [28] was close to signifi cance. This association may be explained by the fact that in Armenia males are more likely to work outside the home; presumably, once their health improves they seek employment, sometimes outside the country. Going back to work was one of the main reasons for treatment default reported by the adherence team. Furthermore, 14.5% of Armenian families have a family member who is a migrant worker, usually male, and mostly in the Russian Federation (93.0%). 29 A recent study showed that 13.9% of migrant workers receiving ambulatory anti-tuberculosis treatment did not complete treatment. 29 Substance abuse is another factor that can explain the association between male sex and defaulting. 30 Patients' behavioural reasons were also reported by the programme adherence team as a reason for defaulting from treatment. In Armenia, 28% of patients are ex-prisoners, half are regular alcohol consumers and almost 5% are users of illicit drugs (NTP/MSF programme data), all conditions that can make treatment adherence diffi cult. 14, 31, 32 It has been proposed that interventions to treat substance abuse during anti-tuberculosis treatment might improve treatment outcomes. 14 Staff perception that some defaulters were failing treatment needs further assessment. In a study in Peru, 
Consumption of alcohol or illicit drugs
There is one factor with defaulter: narcotic drugs and alcohol. If the patient is a drug user or alcoholic, this is a factor of having defaulters. And also we have a group of patients with whom alcohol and drug abuse is preventing us to work with them.
Defaulting due to other factors: feeling already cured, duration of treatment
The patient is not feeling the difference. They think they are already cured. Two years of treatment is unbearable. The treatment is very long.
authors re-assessed MDR-TB treatment outcomes using culture results according to WHO defi nitions. They showed a poor concordance with outcomes reported by the programme. 33 Even with a very good recording system, with the current WHO defi nitions, treatment failures are identifi ed late, and some true failures are defaulting before being classifi ed as failures. 7 The WHO has now revised the defi nition of treatment failure, allowing a patient to be classifi ed as such much earlier. 34 One of the main limitations of the study is the use of a retrospective cohort design based on programme data, which may have affected the quality of data recording. It also prevented a deeper assessment of the role of the social determinants of treatment adherence. Due to the diffi culty in tracing patients who had defaulted a long time ago, only a small proportion of defaulters could be interviewed, and these may not be representative of all defaulters of the DR-TB programme. Nonetheless, the fi ndings of the qualitative survey support the results of the quantitative study. Unfortunately, due to the study design, we could not analyse the possible impact of adherence-promoting interventions, such as food support.
In conclusion, our study found that the risk of defaulting from DR-TB treatment in Yerevan was mainly linked to poor treatment tolerability and effectiveness and to the social determinants of the patients. The advent of new anti-tuberculosis drugs such as delamanid and bedaquiline should allow the development of more effective, better tolerated and shorter treatment regimens for DR-TB, which would also improve treatment adherence. [35] [36] [37] [38] In addition, reinforced communication, with closer and regular contact between health services and the patient, including substance abuse treatment, during the out-patient phase should help reduce default rates.
